GH Research PLC (NASDAQ:GHRS) Receives $34.11 Consensus Price Target from Brokerages

Shares of GH Research PLC (NASDAQ:GHRS) have been given an average rating of “Moderate Buy” by the twelve ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $34.1111.

Several analysts have commented on GHRS shares. Needham & Company LLC set a $29.00 target price on shares of GH Research in a research note on Tuesday, January 6th. Canaccord Genuity Group upped their target price on GH Research from $35.00 to $39.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Wolfe Research set a $39.00 target price on GH Research in a research report on Tuesday, January 6th. TD Cowen reissued a “buy” rating on shares of GH Research in a research note on Monday, January 5th. Finally, Royal Bank Of Canada upped their price objective on shares of GH Research from $33.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd.

Hedge Funds Weigh In On GH Research

A number of large investors have recently bought and sold shares of the stock. Stempoint Capital LP acquired a new stake in shares of GH Research during the second quarter valued at about $1,229,000. AdvisorShares Investments LLC grew its stake in GH Research by 15.0% during the 2nd quarter. AdvisorShares Investments LLC now owns 38,256 shares of the company’s stock valued at $466,000 after purchasing an additional 5,000 shares in the last quarter. CenterBook Partners LP purchased a new stake in GH Research during the 3rd quarter worth approximately $2,376,000. Virtus Investment Advisers LLC acquired a new position in shares of GH Research in the 2nd quarter valued at approximately $89,000. Finally, HighVista Strategies LLC purchased a new position in shares of GH Research during the 2nd quarter valued at approximately $637,000. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Trading Down 1.3%

GH Research stock opened at $15.60 on Friday. The stock has a 50-day moving average price of $14.90 and a 200 day moving average price of $14.04. GH Research has a 52 week low of $7.98 and a 52 week high of $19.51. The stock has a market cap of $811.67 million, a PE ratio of -21.08 and a beta of 0.99.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.